
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6187860/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 38-46.	5.6	150
2	Sputum autoantibodies in patients with severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 2018, 141, 1269-1279.	2.9	93
3	Eosinophil Extracellular Traps and Inflammatory Pathologies—Untangling the Web!. Frontiers in Immunology, 2018, 9, 2763.	4.8	90
4	Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma. Journal of Allergy and Clinical Immunology, 2018, 141, 1529-1532.e8.	2.9	80
5	Autoimmune Responses in Severe Asthma. Allergy, Asthma and Immunology Research, 2018, 10, 428.	2.9	77
6	CT and Functional MRI to Evaluate AirwayÂMucus in Severe Asthma. Chest, 2019, 155, 1178-1189.	0.8	77
7	Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. European Respiratory Journal, 2020, 56, 2000117.	6.7	71
8	Anti-IL5 therapy for asthma and beyond. World Allergy Organization Journal, 2014, 7, 32.	3.5	68
9	Thymic stromal lymphopoietin and IL-33 modulate migration of hematopoietic progenitor cells in patients with allergic asthma. Journal of Allergy and Clinical Immunology, 2015, 135, 1594-1602.	2.9	63
10	Blood or sputum eosinophils to guide asthma therapy?. Lancet Respiratory Medicine,the, 2015, 3, 824-825.	10.7	60
11	Evaluation of air-interfaced Calu-3 cell layers for investigation of inhaled drug interactions with organic cation transporters in vitro. International Journal of Pharmaceutics, 2012, 426, 7-14.	5.2	47
12	Eosinophil-derived IL-13 promotes emphysema. European Respiratory Journal, 2019, 53, 1801291.	6.7	47
13	Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy. Allergy, Asthma and Clinical Immunology, 2017, 13, 2.	2.0	46
14	Sputum Antineutrophil Cytoplasmic Antibodies in Serum Antineutrophil Cytoplasmic Antibody–Negative Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 158-170.	5.6	43
15	Clucocortiosteroid subsensitivity and asthma severity. Current Opinion in Pulmonary Medicine, 2017, 23, 78-88.	2.6	37
16	Asthma exacerbations on benralizumab are largely nonâ€eosinophilic. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 375-379.	5.7	36
17	The Role of the TL1A/DR3 Axis in the Activation of Group 2 Innate Lymphoid Cells in Subjects with Eosinophilic Asthma. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1105-1114.	5.6	35
18	Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma. Immunology and Allergy Clinics of North America, 2018, 38, 639-654.	1.9	30

#	Article	IF	CITATIONS
19	Improved recovery of functionally active eosinophils and neutrophils using novel immunomagnetic technology. Journal of Immunological Methods, 2017, 449, 44-55.	1.4	29
20	Human Bronchial Epithelial Cell–derived Factors from Severe Asthmatic Subjects Stimulate Eosinophil Differentiation. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 99-106.	2.9	28
21	Biologics in Asthma: A Molecular Perspective to Precision Medicine. Frontiers in Pharmacology, 2021, 12, 793409.	3.5	28
22	Dupilumab, severe asthma airway responses, and SARSâ€CoVâ€⊋ serology. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 957-958.	5.7	26
23	Omalizumab in patients with severe asthma and persistent sputum eosinophilia. Allergy, Asthma and Clinical Immunology, 2019, 15, 21.	2.0	15
24	New paradigm in asthma management: Switching between biologics!. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 743-745.	5.7	15
25	Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma. European Respiratory Journal, 2022, 60, 2102446.	6.7	15
26	Non-Malignant Respiratory Illnesses in Association with Occupational Exposure to Asbestos and Other Insulating Materials: Findings from the Alberta Insulator Cohort. International Journal of Environmental Research and Public Health, 2020, 17, 7085.	2.6	13
27	Exacerbations of Severe Asthma While on Anti–IL-5 Biologics. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 307-316.	1.3	13
28	Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1294-1297.	5.7	13
29	Iron in airway macrophages and infective exacerbations of chronic obstructive pulmonary disease. Respiratory Research, 2022, 23, 8.	3.6	13
30	Enhanced expression of Organic Cation Transporters in bronchial epithelial cell layers following insults associated with asthma – Impact on salbutamol transport. European Journal of Pharmaceutical Sciences, 2017, 106, 62-70.	4.0	12
31	Underestimation of airway luminal eosinophilia by quantitative sputum cytometry. Allergy, Asthma and Clinical Immunology, 2021, 17, 63.	2.0	12
32	In-cell Westernâ"¢ detection of organic cation transporters in bronchial epithelial cell layers cultured at an air–liquid interface on Transwell ® inserts. Journal of Pharmacological and Toxicological Methods, 2013, 68, 184-189.	0.7	11
33	Modulation of human airway smooth muscle biology by human adipocytes. Respiratory Research, 2018, 19, 33.	3.6	10
34	Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections. Viruses, 2021, 13, 2239.	3.3	10
35	Endogenous peroxidases in sputum interfere with horse-radish peroxidase-based ELISAs. Journal of Immunological Methods, 2018, 454, 76-79.	1.4	8
36	Airway autoantibodies are determinants of asthma severity. European Respiratory Journal, 2022, 60, 2200442.	6.7	7

#	Article	IF	CITATIONS
37	Rapid quantification of sputum eosinophil peroxidase on a lateral flow test strip. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1176-1178.	5.7	6
38	Sputum and serum immunoglobulins in adult asthmatics with recurrent respiratory tract infections. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2105-2108.	5.7	6
39	Sputum autoantibody-mediated macrophage dysfunction in severe eosinophilic asthmatics with recurrent infections. Journal of Allergy and Clinical Immunology, 2019, 143, AB189.	2.9	5
40	Luminal Eosinophil Cell Death as a Biomarker for Loss of Asthma Control?. Chest, 2020, 157, 1680-1681.	0.8	4
41	ILâ€13 signature in severe adult asthmatics with airway neutrophilia: A new endotype to treat!. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1964-1966.	5.7	4
42	Differential expression of sputum and serum autoantibodies in patients with chronic obstructive pulmonary disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L1169-L1182.	2.9	4
43	Eosinophils as potential mediators of autoimmunity in eosinophilic lung disease. , 2022, , 219-237.		4
44	Detecting immunoglobulins in processed sputa. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3798-3800.	5.7	3
45	Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity. European Respiratory Journal, 2022, 59, 2102210.	6.7	3
46	Pathogenic Autoantibodies in Patients with Severe Asthma and Sputum Eosinophils. Journal of Allergy and Clinical Immunology, 2016, 137, AB409.	2.9	2
47	Human Bronchial Epithelial Cell-Derived Factors from Severe Asthmatics Can Stimulate Local Eosinophilopoetic Responses. Journal of Allergy and Clinical Immunology, 2015, 135, AB148.	2.9	1
48	High Failure Rate of Anti-IL-5 Therapies in Prednisone-Dependent Asthma Is Associated with Airway Autoimmune Responses. , 2019, , .		1
49	Functionally Active Eosinophil Purification from Peripheral Blood. Methods in Molecular Biology, 2021, 2241, 15-25.	0.9	1
50	Weight-adjusted Intravenous Reslizumab Attenuates Airway Eosinophilia in Severe Asthmatics compared to 100 mg Subcutaneous Mepolizumab. , 2017, , .		1
51	CD6-ALCAM Pathway is Elevated in Patients with Severe Asthma. , 2020, , .		1
52	Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma. , 2020, , .		1
53	Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps. , 2020, , .		1
54	Eosinophil Peroxidase As an Autoimmune Target in Eosinophilic Airway Disorders. Journal of Allergy and Clinical Immunology, 2015, 135, AB221.	2.9	0

#	Article	IF	CITATIONS
55	WS1_1 Sputum Anti-neutrophil Cytoplasmic Antibodies (ANCA) in Eosinophilic Granulamatosis and Polyangiitis (eGPA). Rheumatology, 2017, 56, iii17-iii19.	1.9	0
56	Omalizumab in Patients with Severe Asthma and Persistent Sputum Eosinophilia. Journal of Allergy and Clinical Immunology, 2019, 143, AB434.	2.9	0
57	Sputum and serum immunoglobulins in patients with asthma and recurrent neutrophilic bronchitis. Journal of Allergy and Clinical Immunology, 2019, 143, AB227.	2.9	0
58	Increased B-Cells in the Airways of Patients with Severe Eosinophilic Asthma: A Local Auto-Inflammatory Process. , 2019, , .		0
59	Airway Luminal Contributors to Magnetic Resonance Imaging Ventilation Heterogeneity in Severe Asthma. , 2019, , .		0
60	Autoantigen Array Reveals Decreased Expression of Autoantibodies in Sputum of Patients with Chronic Obstructive Pulmonary Disease. , 2019, , .		0
61	TL1A/DR3 Axis Promotes Group 2 Innate Lymphocyte Activation in Eosinophilic Asthmatics. , 2020, , .		0
62	The Role of Excess Airway Macrophage Iron on Infective Exacerbations of Chronic Obstructive Pulmonary Disease. , 2020, , .		0
63	Notch4, uncovering an immunomodulator in allergic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3852-3854.	5.7	0
64	Clinical relevance of sputum bronchial epithelial cells: A retrospective cross-sectional study. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 35-40.	0.5	0
65	Benralizumab attenuates airway eosinophilopoietic processes in prednisone-dependent asthma. , 2017, ,		0
66	Increased sputum B cells in severe eosinophilic asthma: a local auto-inflammatory process. , 2018, , .		0
67	A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma. , 2019, , .		0
68	The Inability to Limit Autoimmune Pathology Is Associated with COVID-19 Hospital Fatality. , 2022, , .		0
69	Circulating Autoantibodies in Post-Acute Sequelae of COVID-19. , 2022, , .		0
70	Eosinophil-Independent IL-5 Increase in Critically III COVID-19 Patients Associates with Favourable Outcome. , 2022, , .		0
71	Ventilation and perfusion abnormalities following recovery from noncritical COVID-19. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 0, , 1-10.	0.5	0